EyePoint Pharmaceuticals Inc
EYPT18.260USD
-0.120-0.65%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.27BMarket Cap
LossP/E TTM
More Details of EyePoint Pharmaceuticals Inc Company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc Info
Ticker SymbolEYPT
Company nameEyePoint Pharmaceuticals Inc
IPO dateJan 27, 2005
CEODuker (Jay S)
Number of employees165
Security typeOrdinary Share
Fiscal year-endJan 27
Address480 Pleasant Street, Suite C400
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16179265000
Websitehttps://eyepointpharma.com/
Ticker SymbolEYPT
IPO dateJan 27, 2005
CEODuker (Jay S)
Company Executives of EyePoint Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
565.46K
-1.62%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
39.06K
-6.51%
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
565.46K
-1.62%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
YUTIQ
3.10M
7.16%
By RegionUSD
Name
Revenue
Proportion
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
YUTIQ
3.10M
7.16%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
9.98%
Suvretta Capital Management, LLC
7.48%
Adage Capital Management, L.P.
6.72%
BlackRock Institutional Trust Company, N.A.
5.17%
Franklin Advisers, Inc.
5.00%
Other
65.65%
Shareholders
Shareholders
Proportion
Cormorant Asset Management, LP
9.98%
Suvretta Capital Management, LLC
7.48%
Adage Capital Management, L.P.
6.72%
BlackRock Institutional Trust Company, N.A.
5.17%
Franklin Advisers, Inc.
5.00%
Other
65.65%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.77%
Investment Advisor
23.90%
Investment Advisor/Hedge Fund
19.30%
Research Firm
4.43%
Private Equity
3.39%
Individual Investor
2.73%
Venture Capital
2.58%
Bank and Trust
1.06%
Pension Fund
0.13%
Other
9.71%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
363
69.86M
126.07%
--
2025Q3
373
69.94M
127.01%
+1.23K
2025Q2
381
69.95M
127.71%
-5.27M
2025Q1
371
75.32M
126.89%
-11.89M
2024Q4
359
75.24M
109.81%
+11.20M
2024Q3
343
59.71M
126.62%
+193.11K
2024Q2
330
60.06M
120.79%
+1.75M
2024Q1
313
56.72M
108.78%
+2.51M
2023Q4
268
50.21M
76.86%
+16.41M
2023Q3
224
33.81M
98.97%
+2.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cormorant Asset Management, LP
8.32M
12.08%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
6.80M
9.87%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.80M
9.87%
+600.00K
+9.68%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.60M
6.67%
-346.31K
-7.00%
Jun 30, 2025
Franklin Advisers, Inc.
4.27M
6.19%
+148.48K
+3.60%
Jun 30, 2025
The Vanguard Group, Inc.
3.80M
5.52%
-15.98K
-0.42%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
3.58M
5.2%
-128.17K
-3.45%
Jun 30, 2025
TCG Crossover Management, LLC
3.57M
5.18%
--
--
Jun 30, 2025
Citadel Advisors LLC
2.34M
3.4%
+58.12K
+2.54%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1%
Simplify Health Care ETF
0.99%
State Street SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.15%
iShares Health Innovation Active ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1%
Simplify Health Care ETF
Proportion0.99%
State Street SPDR S&P Pharmaceuticals ETF
Proportion0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.36%
Federated Hermes MDT Small Cap Core ETF
Proportion0.3%
iShares Micro-Cap ETF
Proportion0.15%
iShares Health Innovation Active ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Date
Type
Ratio
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
FAQs
Who are the top five shareholders of EyePoint Pharmaceuticals Inc?
The top five shareholders of EyePoint Pharmaceuticals Inc are:
Cormorant Asset Management, LP holds 8.32M shares, accounting for 12.08% of the total shares.
Suvretta Capital Management, LLC holds 6.80M shares, accounting for 9.87% of the total shares.
Adage Capital Management, L.P. holds 6.80M shares, accounting for 9.87% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.60M shares, accounting for 6.67% of the total shares.
Franklin Advisers, Inc. holds 4.27M shares, accounting for 6.19% of the total shares.
Cormorant Asset Management, LP holds 8.32M shares, accounting for 12.08% of the total shares.
Suvretta Capital Management, LLC holds 6.80M shares, accounting for 9.87% of the total shares.
Adage Capital Management, L.P. holds 6.80M shares, accounting for 9.87% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.60M shares, accounting for 6.67% of the total shares.
Franklin Advisers, Inc. holds 4.27M shares, accounting for 6.19% of the total shares.
What are the top three shareholder types of EyePoint Pharmaceuticals Inc?
The top three shareholder types of EyePoint Pharmaceuticals Inc are:
Cormorant Asset Management, LP
Suvretta Capital Management, LLC
Adage Capital Management, L.P.
Cormorant Asset Management, LP
Suvretta Capital Management, LLC
Adage Capital Management, L.P.
How many institutions hold shares of EyePoint Pharmaceuticals Inc (EYPT)?
As of 2025Q4, 363 institutions hold shares of EyePoint Pharmaceuticals Inc, with a combined market value of approximately 69.86M, accounting for 126.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.94%.
What is the biggest source of revenue for EyePoint Pharmaceuticals Inc?
In FY2024, the YUTIQ business generated the highest revenue for EyePoint Pharmaceuticals Inc, amounting to 3.10M and accounting for 7.16% of total revenue.
